Pharmaceutical
Technology
Health

Catabasis

$7.45
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.34 (4.78%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Catabasis and other stocks, options, ETFs, and crypto commission-free!

About

Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. Read More The company was founded by Jill C. Milne, Michael Jirousek, and Steven Shoelson on June 26, 2008 and is headquartered in Cambridge, MA.

Employees
24
Headquarters
Cambridge, Massachusetts
Founded
2008
Market Cap
50.78M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
98.19K
High Today
$7.73
Low Today
$7.20
Open Price
$7.24
Volume
207.83K
52 Week High
$20.70
52 Week Low
$3.60

Collections

Pharmaceutical
Technology
Health
Biotechnology
Medical
Biopharmaceutical
Therapy
2015 IPO

News

Yahoo FinanceMar 19

Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight

For Immediate Release Chicago, IL – March 19, 2019 - Stocks in this week’s article are Catabasis Pharmaceuticals Inc. CATB, Ligand Pharmaceuticals Inc. LGND, Key Energy Services Inc. KEG, Carbonite Inc. CARB and Second Sight Medical Products Inc. EYES. Rising P/E an Overlooked Criterion: 5 Top Stocks Trying hands at bargain stocks that have a low price-to-earnings (P/E) ratio is a common practice. The perception is that the lower the P/E, the higher will be the value of the stock. This inference is drawn...

62
Simply Wall StMar 15

What Kind Of Shareholders Own Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB)?

The big shareholder groups in Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. Companies that have been privatized tend to have low insider ownership. Catabasis Pharmaceuticals is a smaller company with a market capitalization of US$65m, so it may still be flying under the radar of many institutional investors. Our analysis of the ownership of t...

130
Seeking AlphaMar 14

Catabasis Pharmaceuticals' (CATB) CEO Jill Milne on Q4 2018 Results - Earnings Call Transcript

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Q4 2018 Earnings Conference Call March 14, 2019 8:30 AM ET Company Participants Andrea Matthews – Vice President-Corporate Affairs Jill Milne – Chief Executive Officer Joanne Donovan – Chief Medical Officer Andrew Nichols – Chief Scientific Officer Noah Clauser – Vice President of Finance Conference Call Participants Hartaj Singh – Oppenheimer Joel Beatty – Citi Operator Good day, ladies and gentlemen, and welcome to the Q4 2018 Catabasis Pharmaceutic...

93

Earnings

-$0.90
-$0.63
-$0.35
-$0.08
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.90 per share
Actual
-$0.85 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.